SBS: Annual General Meeting of STRATEC passes resolution to issue bonus shares

STRATEC increases distribution to shareholders by 50%

The Annual General Meeting of STRATEC Biomedical Systems AG held on
Friday passed all of the agenda items requiring shareholders'
approval in each case with a considerable majority.

STRATEC will be distributing Euro 0.30 per share to its shareholders
for the 2005 financial year (previous year: dividend of Euro 0.15,
plus bonus of Euro 0.05). This represents a 50% increase in the
distribution per share compared with the previous year.

The Annual General Meeting further approved the issue of bonus
shares. As soon as the corresponding resolution has become effective
upon being entered in the Commercial Register, each shareholder will
receive an additional two new shares (bonus shares) for each existing
share. This means that the volumes of STRATEC shares held in
shareholders' security accounts will automatically treble. No
contribution will be required from shareholders in this respect. The
issue of bonus shares is intended to make the share more attractive
for investors and to facilitate trading with the share. The execution
of this measure will increase STRATEC's share capital from its
current level of Euro 3,708,239.00 to Euro 11,124,717.00.

Moreover, STRATEC's shareholders also adopted a resolution
authorizing the company's Board of Management to buy back treasury
stock and a resolution allowing the granting of stock options and the
creation of new conditional capital to service stock option rights.
In addition, the shareholders approved the restructuring of
supervisory board remuneration, the creation of new authorized
capital and a resolution authorizing the Board of Management to issue
convertible and warrant bonds. Furthermore, the shareholders
authorized the Board of Management to refrain from publishing the
remuneration of the Board of Management and the Supervisory Board on
an individual basis. Finally, the shareholders approved various
amendments to the company's articles of association, particularly
with regard to the entry into force of the Act on Corporate Integrity
and Modernization of the Right of Contestation (UMAG).

About STRATEC

STRATEC Biomedical Systems AG (http://www.stratec-biomedical.de)
designs and manufactures fully automated systems for its partners in
the fields of clinical diagnostics and biotechnology. These partners
market such systems, in general together with their own reagents, to
laboratories and research institutes around the world. The company
develops its products on the basis of its own patented technologies.
Shares in the company (SIN: 728900 / ISIN: DE0007289001) are traded
in the Prime Standard segment of the Frankfurt Stock Exchange, in the
Gate-M trading segment of the Stuttgart Stock Exchange and on other
exchanges.

The STRATEC Group comprises the listed holding company "STRATEC
Biomedical Systems AG", as well as the subsidiaries "STRATEC NewGen",
"Robion" and "Sanguin".

Further information can be obtained from:

STRATEC Biomedical Systems AG
André Loy, Investor Relations
Gewerbestrasse 37, 75217 Birkenfeld
Germany
Tel: +49 7082 7916-190
Fax: +49 7082 7916-999
E-Mail: ir@stratec-biomedical.de